Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis
Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]